Hoth Therapeutics’ (HOTH) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research report sent to investors on Monday, Benzinga reports. They currently have a $4.00 target price on the stock. HC Wainwright also issued estimates for Hoth Therapeutics’ Q2 2024 earnings at ($0.39) EPS, Q3 2024 earnings at ($0.36) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings at ($1.40) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.86) EPS.

Hoth Therapeutics Stock Performance

Hoth Therapeutics stock opened at $1.07 on Monday. Hoth Therapeutics has a 1 year low of $0.72 and a 1 year high of $3.37. The firm has a 50 day moving average price of $1.01 and a 200 day moving average price of $1.20. The company has a market cap of $5.73 million, a price-to-earnings ratio of -0.47 and a beta of 0.80.

Hoth Therapeutics (NASDAQ:HOTH) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Sell-side analysts predict that Hoth Therapeutics will post -1.65 EPS for the current year.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.